TY - JOUR A1 - Neubert, Sven A1 - Schlecht, Sina A1 - Meng, Karin A1 - Rabe, Antonia A1 - Jentschke, Elisabeth T1 - Effects of a video sequence based intervention on anxiety, fatigue and depression in cancer patients: results of a randomized controlled trial JF - Integrative Cancer Therapies N2 - Background: Cancer patients often suffer from psychological symptoms and need psychological support. Especially during the COVID-19 pandemic, eHealth interventions might be helpful to overcome the obstacles of the pandemic. This study evaluates the effectiveness of a video sequence-based eHealth intervention on anxiety, fatigue, and depression in cancer patients. Methods: Patients (N = 157) with different tumor entities were randomly assigned to the video intervention group (IG) and the waiting control group (CG). Patients in the IG received a video intervention comprising 8 video sequences over 4 weeks. The videos included psychoeducation on distress and psychological symptoms, Acceptance and Commitment Therapy elements, and Yoga and Qigong exercises. Patients’ anxiety and fear of progression (primary outcomes) and secondary outcomes were assessed before randomization (T1) and after the end of the intervention for IG or the waiting period for CG (T2) using self-reported questionnaires (GAD-7, PA-F-KF, EORTC QLQ-FA12, PHQ-8). Results: Patients of the IG showed no significant improvement in anxiety (GAD-7; P = .75), fear of progression (FoP-Q-SF; P = .29), fatigue (EORTC QLQ-FA12; P = .72), and depression (PHQ-8; P = .95) compared to patients in the waiting CG. However, symptoms of anxiety, fatigue, and depression decreased in both groups. Exploratory subgroup analysis regarding sex, therapy status, therapy goal, and tumor entity showed no effects. Overall, the intervention had a high level of acceptance. Conclusions: The video intervention was ineffective in reducing the psychological burden compared to a waiting CG. The findings support prior observations of the value of therapeutic guidance and promoting self-management for improving patients’ psychological burdens. Further studies are required to evaluate the effectiveness of psycho-oncological eHealth delivered through video sequences. KW - eHealth KW - psycho-oncology KW - complementary medicine KW - psychoeducation KW - mind-body-intervention KW - anxiety KW - depression KW - fatigue KW - oncology Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-304581 SN - 1552-695X VL - 22 ER - TY - JOUR A1 - Kerwagen, Fabian A1 - Riemer, Uwe A1 - Wachter, Rolf A1 - von Haehling, Stephan A1 - Abdin, Amr A1 - Böhm, Michael A1 - Schulz, Martin A1 - Störk, Stefan T1 - Impact of the COVID-19 pandemic on implementation of novel guideline-directed medical therapies for heart failure in Germany: a nationwide retrospective analysis JF - The Lancet Regional Health - Europe N2 - Background Guideline-directed medical therapy (GDMT) is the cornerstone in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) and novel substances such as sacubitril/valsartan (S/V) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) have demonstrated marked clinical benefits. We investigated their implementation into real-world HF care in Germany before, during, and after the COVID-19 pandemic period. Methods The IQVIA LRx data set is based on ∼80% of 73 million people covered by the German statutory health insurance. Prescriptions of S/V were used as a proxy for HFrEF. Time trends were analysed between Q1/2016 and Q2/2023 for prescriptions for S/V alone and in combination therapy with SGLT2i. Findings The number of patients treated with S/V increased from 5260 in Q1/2016 to 351,262 in Q2/2023. The share of patients with combination therapy grew from 0.6% (29 of 5260) to 14.2% (31,128 of 219,762) in Q2/2021, and then showed a steep surge up to 54.8% (192,429 of 351,262) in Q2/2023, coinciding with the release of the European Society of Cardiology (ESC) guidelines for HF in Q3/2021. Women and patients aged >80 years were treated less often with combined therapy than men and younger patients. With the start of the COVID-19 pandemic, the number of patients with new S/V prescriptions dropped by 17.5% within one quarter, i.e., from 26,855 in Q1/2020 to 22,145 in Q2/2020, and returned to pre-pandemic levels only in Q1/2021. Interpretation The COVID-19 pandemic was associated with a 12-month deceleration of S/V uptake in Germany. Following the release of the ESC HF guidelines, the combined prescription of S/V and SGLT2i was readily adopted. Further efforts are needed to fully implement GDMT and strengthen the resilience of healthcare systems during public health crises. KW - health policy KW - oncology KW - internal medicine KW - heart failure KW - COVID-19 KW - sacubitril-valsartan KW - sodium-glucose co-transporter-2 inhibitors KW - guideline-directed medical therapy KW - evidence-based practice KW - real-world Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-350510 SN - 2666-7762 VL - 35 ER - TY - JOUR A1 - Grapp, Miriam A1 - Ell, Johanna A1 - Kiermeier, Senta A1 - Haun, Markus W. A1 - Kübler, Andrea A1 - Friederich, Hans-Christoph A1 - Maatouk, Imad T1 - Feasibility study of a self-guided internet-based intervention for family caregivers of patients with cancer (OAse) JF - Scientific Reports N2 - Despite high levels of distress, family caregivers of patients with cancer rarely seek psychosocial support and Internet-based interventions (IBIs) are a promising approach to reduce some access barriers. Therefore, we developed a self-guided IBI for family caregivers of patients with cancer (OAse), which, in addition to patients' spouses, also addresses other family members (e.g., adult children, parents). This study aimed to determine the feasibility of OAse (recruitment, dropout, adherence, participant satisfaction). Secondary outcomes were caregivers’ self-efficacy, emotional state, and supportive care needs. N = 41 family caregivers participated in the study (female: 65%), mostly spouses (71%), followed by children (20%), parents (7%), and friends (2%). Recruitment (47%), retention (68%), and adherence rates (76% completed at least 4 of 6 lessons) support the feasibility of OAse. Overall, the results showed a high degree of overall participant satisfaction (96%). There were no significant pre-post differences in secondary outcome criteria, but a trend toward improvement in managing difficult interactions/emotions (p = .06) and depression/anxiety (p = .06). Although the efficacy of the intervention remains to be investigated, our results suggest that OAse can be well implemented in caregivers’ daily lives and has the potential to improve family caregivers’ coping strategies. KW - cancer KW - oncology KW - psychology Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300537 VL - 12 ER - TY - JOUR A1 - Augustin, Anne Marie A1 - Lucius, Leonie Johanna A1 - Thurner, Annette A1 - Kickuth, Ralph T1 - Malignant obstruction of the inferior vena cava: clinical experience with the self-expanding Sinus-XL stent system JF - Abdominal Radiology N2 - Purpose To evaluate the technical and clinical outcome of Sinus-XL stent placement in patients with malignant obstruction syndrome of the inferior vena cava. Methods Between October 2010 and January 2021, 21 patients with different malignant primary disease causing inferior vena cava obstruction were treated with Sinus-XL stent implantation. Procedural data, technical and clinical outcome parameters were retrospectively analyzed. Results Technical success was 100%. Analysis of available manometry data revealed a significant reduction of the mean translesional pressure gradient following the procedure (p = 0.008). Reintervention rate was 4.8% (1/21). The available follow-up imaging studies showed primary and primary-assisted stent patency rates of 93% (13/14) and 100% (14/14), respectively. Major complications did not occur. The clinical success regarding lower extremity edema was 82.4% (14/17) for the first and 85.7% (18/21) for the last follow-up. Longer lengths of IVC obstruction were associated with reduced clinical improvement after the procedure (p = 0.025). Improvement of intraprocedural manometry results and lower extremity edema revealed only minor correlation. Ascites and anasarca were not significantly positively affected by the procedure. Conclusion Sinus-XL stent placement in patients with malignant inferior vena cava obstruction showed high technical success and low complication rates. Regarding the clinical outcome, significant symptom improvement could be achieved in lower extremity edema, whereas ascites and anasarca lacked satisfying symptom relief. Based on our results, this procedure should be considered as a suitable therapy in a palliative care setting for patients with advanced malignant disease. KW - endovascular KW - inferior vena cava KW - interventional procedures KW - oncology KW - palliative care KW - stent Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-324951 VL - 47 IS - 10 ER - TY - JOUR A1 - Esser, Peter A1 - Mehnert‐Theuerkauf, Anja A1 - Friedrich, Michael A1 - Johansen, Christoffer A1 - Brähler, Elmar A1 - Faller, Hermann A1 - Härter, Martin A1 - Koch, Uwe A1 - Schulz, Holger A1 - Wegscheider, Karl A1 - Weis, Joachim A1 - Kuba, Katharina A1 - Hinz, Andreas A1 - Hartung, Tim T1 - Risk and associated factors of depression and anxiety in men with prostate cancer: Results from a German multicenter study JF - Psycho‐Oncology N2 - Objective In order to optimize psycho‐oncological care, studies that quantify the extent of distress and identify certain risk groups are needed. Among patients with prostate cancer (PCa), findings on depression and anxiety are limited. Methods We analyzed data of PCa patients selected from a German multi‐center study. Depression and anxiety were assessed with the PHQ‐9 and the GAD‐7 (cut‐off ≥7). We provided physical symptom burden, calculated absolute and relative risk (AR and RR) of depression and anxiety across patient subsets and between patients and the general population (GP) and tested age as a moderator within the relationship of disease‐specific symptoms with depression and anxiety. Results Among 636 participants, the majority reported disease‐specific problems (sexuality: 60%; urination: 52%). AR for depression and anxiety was 23% and 22%, respectively. Significant RR were small, with higher risks of distress in patients who are younger (eg, RR\(_{depression}\) = 1.15; 95%‐CI: 1.06‐1.26), treated with chemotherapy (RR\(_{depression}\)n = 1.46; 95%‐CI: 1.09‐1.96) or having metastases (RR\(_{depression}\) = 1.30; 95%‐CI: 1.02‐1.65). Risk of distress was slightly elevated compared to GP (eg, RR\(_{depression}\) = 1.13; 95%‐CI: 1.07‐1.19). Age moderated the relationship between symptoms and anxiety (B\(_{urination}\) = −0.10, P = .02; B\(_{sexuality}\) = −0.11, P = .01). Conclusions Younger patients, those with metastases or treatment with chemotherapy seem to be at elevated risk for distress and should be closely monitored. Many patients suffer from disease‐specific symptom burden, by which younger patients seem to be particularly distressed. Support of coping mechanisms associated with disease‐specific symptom burden seems warranted. KW - anxiety KW - cancer KW - depression KW - oncology KW - prostatic neoplasms Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-218277 VL - 29 IS - 10 SP - 1604 EP - 1612 ER - TY - JOUR A1 - Heß, Verena A1 - Meng, Karin A1 - Schulte, Thomas A1 - Neuderth, Silke A1 - Bengel, Jürgen A1 - Faller, Hermann A1 - Schuler, Michael T1 - Prevalence and predictors of cancer patients' unexpressed needs in the admission interview of inpatient rehabilitation JF - Psycho‐Oncology N2 - Objective The admission interview in oncological inpatient rehabilitation might be a good opportunity to identify cancer patients' needs present after acute treatment. However, a relevant number of patients may not express their needs. In this study, we examined (a) the proportion of cancer patients with unexpressed needs, (b) topics of unexpressed needs and reasons for not expressing needs, (c) correlations of not expressing needs with several patient characteristics, and (d) predictors of not expressing needs. Methods We enrolled 449 patients with breast, prostate, and colon cancer at beginning and end of inpatient rehabilitation. We obtained self‐reports about unexpressed needs and health‐related variables (quality of life, depression, anxiety, adjustment disorder, and health literacy). We estimated frequencies and conducted correlation and ordinal logistic regression analyses. Results A quarter of patients stated they had “rather not” or “not at all” expressed all relevant needs. Patients mostly omitted fear of cancer recurrence. Most frequent reasons for not expressing needs were being focused on physical consequences of cancer, concerns emerging only later, and not knowing about the possibility of talking about distress. Not expressing needs was associated with several health‐related outcomes, for example, emotional functioning, adjustment disorder, fear of progression, and health literacy. Depression measured at the beginning of rehabilitation showed only small correlations and is therefore not sufficient to identify patients with unexpressed needs. Conclusions A relevant proportion of cancer patients reported unexpressed needs in the admission interview. This was associated with decreased mental health. Therefore, it seems necessary to support patients in expressing needs. KW - cancer KW - inpatient rehabilitation KW - oncology KW - prediction KW - prevalence KW - unexpressed needs Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-228369 VL - 29 IS - 10 SP - 1549 EP - 1556 ER - TY - JOUR A1 - San-Miguel, Jesus F. A1 - Einsele, Hermann A1 - Moreau, Philippe T1 - The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective JF - Advances in Therapy N2 - Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat acts via epigenetic modification and inhibition of the aggresome pathway. In August 2015, the European Commission authorized panobinostat for use in combination with bortezomib and dexamethasone for the treatment of relapsed or relapsed and refractory multiple myeloma (MM) in patients who have received aeyen2 prior regimens including bortezomib and an immunomodulatory drug. In January 2016, the National Institute for Health and Care Excellence recommended panobinostat for use in the same combination and patient population. The authorization and recommendation were based on results from the pivotal phase 3 PANORAMA 1 (NCT01023308) clinical trial, which demonstrated an improvement in median progression-free survival of 7.8 months for the three-drug combination compared with placebo plus bortezomib and dexamethasone in this patient population. This review will discuss the current treatment landscape for relapsed/refractory MM, the mechanism of action of panobinostat, clinical data supporting the European authorization, concerns about safety and strategies for mitigating toxicity, and how panobinostat fits into the current MM landscape in Europe. KW - multiple myeloma KW - oncology KW - panobinostat KW - relapsed and refractory KW - daratumumab monotherapy KW - relapsed Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-186840 VL - 33 IS - 11 ER - TY - THES A1 - Stein, Lisa-Lena T1 - Partizipationsbedürfnis und wahrgenommene Partizipation -Zusammenhang mit psychischem Befinden und Lebensqualität T1 - Participation preferences and experienced participation - correlation with mental health and quality of life N2 - Im Rahmen von Krebserkrankungen müssen zahlreiche medizinische Entscheidungen getroffen werden. Das Bedürfnis der Patienten, an solchen Entscheidungen zu partizipieren, ist individuell unterschiedlich und für Ärzte häufig schwer einschätzbar. Ziel dieser Arbeit ist eine bessere Vorhersage der Partizipationsbedürfnisse von Krebspatienten und die Untersuchung von Effekten des Partizipationsbedürfnisses auf die Lebensqualität. N2 - In an oncological context many medical decisions have to be made. Patient participation preferences concerning these decisions individually differ. For physicians it is often hard to predict them. The aim of this work is a better prediction of oncological patients' participation preferences. Effects of a congruence of preferred and experienced participation on quality of life are investigated. KW - Partizipation KW - Lebensqualität KW - Quality of life KW - Onkologie KW - Partizipative Entscheidungsfindung KW - psychisches Befinden KW - shared decision making KW - mental health KW - participation KW - oncology Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-83906 ER - TY - THES A1 - Karaaslan, Ferdi T1 - Untersuchungen zum antikanzerogenen Potential von Benzochinonen: Oxidativer Stress als Auslöser zelltoxischer Effekte T1 - Investigation on the anti-cancer potential of benzoquinones: oxidative stress as trigger of cell toxic effects N2 - Die zelltoxische Wirkung von AVEMAR, einem medizinischen Nahrungsergänzungsmittel, wurde erstmalig an einer Vielzahl humaner Tumorzelllinien systematisch untersucht. Die einzelnen Tumorzelllinien reagierten sehr unterschiedlich auf die Inkubation mit AVEMAR. So weisen vier der zwölf Tumorzelllinien (33 %) einen EC50-Wert von mehr als 50 mg/ml auf und waren somit resistent gegenüber AVEMAR, während fünf der zwölf Tumorzelllinien (42 %) einen EC50 Wert von <10 mg/ml aufweisen. Für drei Zelllinien wurde ein EC50-Wert zwischen >10 und <25 mg/ml nachgewiesen. Zwischen der Wachstumsgeschwindigkeit der Zellen und ihrer Empfindlichkeit gegenüber dem AVEMAR-Effekt war kein Zusammenhang zu erkennen; ebenso wurde ausgeschlossen, dass der AVEMAR Effekt auf einer unspezifischen Wirkung beruht. Zur weiteren Untersuchung wurden vier der zwölf Zelllinien ausgewählt: BxPC-3 (EC50: 4,9 +/- 0,42 mg/ml); 23132/87 (EC50: 9,3 +/- 0,28 mg/ml); HT-29 (EC50: 15,35 +/- 0,21 mg/ml) und HRT-18 (EC50: 21,3 +/- 0,42 mg/ml). Die Wirkung von 10 mg/ml AVEMAR auf diese vier Zelllinien war nach einer Inkubationsdauer von 24 Stunden: zelltoxisch (BxPC-3), zytostatisch (23132/87 und HT-29) und schwach zytostatisch (HRT-18). Insbesondere für HRT-18 war der zytostatische Effekt von AVEMAR begrenzt und bereits nach 48 Stunden in Kultur ohne AVEMAR nicht mehr zu beobachten. Im Gegensatz dazu war der zelltoxische Effekt von AVEMAR auf Zellen der Linie BxPC-3 extrem rasch (<24 Stunden) und absolut irreversibel. Dieser zelltoxische Effekt ähnelt der Wirkungsweise von 2,6-Dimethoxy-1,4-Benzochinonen, wobei nicht geklärt ist, ob reaktive Sauerstoffspezies oder andere Formen von Radikalen, z.B. Stickstoffradikale, entstehen. Diese Vermutung wird dadurch gestützt, dass ausschließlich Glutathion, welches als Radikalfänger an zahlreichen enzymabhängigen Reduktionsreaktionen beteiligt ist, die zelltoxische Wirkung von AVEMAR kompensieren konnte. Katalase, die die Detoxifikation von Wasserstoffperoxid katalysiert, zeigte in Gegenwart von AVEMAR keine Wirkung, war aber in Gegenwart von Benzochinonen wirksam. Da bei oxidativem Stress auch Wasserstoffperoxid entsteht, scheint die zelltoxische Wirkung von AVEMAR bei BxPC-3 nicht auf Auslösung von oxidativem Stress zu beruhen, sondern auf der Induktion von Radikalen bzw. toxischen Metaboliten anderer Art. Der bei den Tumorzelllinien 23132/87 und HT-29 beobachtete, weniger aggressive zytostatische Effekt von AVEMAR basiert nicht auf der Induktion freier Radikale, da Glutathion ohne Wirkung war. Mit der Zytostase einhergehend war eine deutliche Verringerung des intrazellulären ATP-Gehalts um bis zu 60 % bei 10 mg/ml bzw. 100 % bei 50 mg/ml AVEMAR. Zusätzlich zur Wirkung von AVEMAR wurden weitere Weizenprodukte auf mögliche zelltoxische bzw. zytostatische Effekte getestet und zwar Weizenkeimlinge, handelsübliches Weizenmehl vom Typ 405 und Weizenlektine. Interessanterweise wurde je nach Zelllinie auch für diese Weizenprodukte ein zelltoxischer Effekt in vitro nachgewiesen. AVEMAR weist zelltoxische und zytostatische Effekte auf. Beide Effekte werden nicht über oxidativen Stress vermittelt. Die zelltoxische Wirkung von AVEMAR wird durch Nicht-Sauerstoffradikale bzw. toxische Metabolite vermittelt. Damit wurde der postulierte Hauptmechanismus von AVEMAR - nämlich die Induktion von oxidativem Stress durch Benzochinone - nicht bestätigt. AVEMAR stellt ein nebenwirkungsarmes, gut verträgliches und günstiges Nahrungsergänzungsmittel dar. Die vorliegende Arbeit, aber auch klinische Studien haben eine Wirksamkeit von AVEMAR gegenüber Tumoren gezeigt. Da zahlreiche onkologische Patienten sehr motiviert sind, neben der Chemo- und Radiotherapie, weitere Maßnahmen gegen ihr Krebsleiden zu ergreifen, sind Empfehlungen von Supportivprodukten, deren zugrunde liegenden Mechanismen weitestgehend aufgeklärt sind und für die ein wissenschaftlicher Nachweis ihrer Wirksamkeit vorliegt, sicherlich ein zu begrüßender Schritt zur ganzheitlichen Betreuung onkologischer Patienten. N2 - The cytotoxic effect of the medical nutriment AVEMAR was investigated on a variety of different human cancer cell lines. The cells of the investigated cell lines reacted very differently to AVEMAR. Four of the twelve (33%) tested cell lines showed an EC50 value above 50 mg/ml and were therefore resistant against AVEMAR, while five of them (42%) showed an EC50 value below 10 mg/ml. Three cell lines showed an EC50 value between 10 and 25 mg/ml. There was no correlation between the growth rate of the cells and the cytotoxic effect of AVEMAR; although there was no evidence that the AVEMAR effect was based on an unspecific protein effect. Four of the twelve tested cell lines were chosen for further investigation: BxPC-3 (EC50: 4,9 +/- 0,42 mg/ml); 23132/87 (EC50: 9,3 +/- 0,28 mg/ml); HT-29 (EC50: 15,35 +/- 0,21 mg/ml) and HRT-18 (EC50: 21,3 +/- 0,42 mg/ml). The observed effect of AVEMAR after an incubation of 24 hours was: cytotoxic (BxPC-3), cytostatic (23132/87 and HT-29) and weakly cytostatic (HRT-18). The cytotoxic effect of AVEMAR was limited, especially for HRT-18, and was no longer present after 48 hours in cell cultures without AVEMAR. In contrast, the cytotoxicity of AVEMAR was fast (<24 hours) and absolutely irreversible on the cell line BxPC-3. The characteristics of the AVEMAR-induced cytotoxicity are similar to the cytotoxic effect induced by 2.6-dimethoxy-1.4-benzoquinones, although there is no proof for the existence of reactive oxygen species or other radicals (e.g. nitrogen radicals). This assumption is based on the significant protective effect of the unspecific radical scavenger glutathione against AVEMAR, which plays a part in many enzyme-dependent redox reactions. Catalase, which is able to detoxicate hydrogen peroxide, showed no protective effect in the presence of AVEMAR, but strong protective effects in the presence of benzoquinones. Since hydrogen peroxide is also formed under oxidative stress, the cytotoxic effect of AVEMAR does not seem to be caused by triggering oxidative stress, but rather by the induction of radicals or toxic metabolites of another kind. The less aggressive cytostatic effect of AVEMAR observed in 23132/87 and HT-29 cells is not based on the induction of free radicals. Evidence for this is the missing protective effect of glutathione. Besides the observed cytostatic effect, a marked reduction in the intracellular content of ATP of up to 60% at a concentration of 10mg/ml AVEMAR, and 100% at 50 mg/ml could be shown. In addition to the effects of AVEMAR, the cytotoxic effects on other wheat products such as wheat germs, wheat flour type 405, and wheat lectins were investigated. Interestingly, depending on the tested cell lines, cytotoxic effects for these wheat products could be shown in vitro. AVEMAR shows both cytotoxic and cytostatic effects, which are not mediated by oxidative stress. The cytotoxic effect of AVEMAR is mediated by radicals or toxic metabolites other than reactive oxygen species. Hence, the postulated main mechanism of AVEMAR – which was the induction of oxidative stress – could not be confirmed. AVEMAR represents a well-tolerated, inexpensive dietary supplement with few side effects. The anti-cancer effect of AVEMAR was shown in this paper, as well as in many in vitro, in vivo and clinical studies. The majority of cancer patients are open to alternatives to radio- and chemotherapy for fighting their disease. This is why the recommendation of supportive products, whose underlying mechanisms are widely solved and whose efficacy is scientifically proven, would be a welcome step towards the holistic treatment of cancer patients. KW - Oxidativer Stress KW - Benzochinone KW - Weizen KW - Antioxidans KW - Onkologie KW - AVEMAR KW - Oxidativer Stress KW - Benzochinone KW - Weizen KW - Antioxidans KW - Onkologie KW - AVEMAR KW - oxidative stress KW - benzoquinones KW - wheat KW - antioxidant KW - oncology Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-79063 ER - TY - THES A1 - Wierlemann, Alexander T1 - Entwicklung eines rechnergestützten Therapiemanagementsystems für die medizinische Onkologie T1 - Developement of a computer-basesd therapy-management system for medical oncology N2 - Durch die Einführung eines neuen fallpauschalierten Abrechnungssystems (Diangnosis related groups, DRG) sowie zahlreiche neue Maßnahmen der Qualitätssicherung wächst der Anteil administrativer Tätigkeiten für die klinisch tätigen Ärztinnen und Ärzte. Diese Entwicklung hat nicht zuletzt auch Auswirkungen auf die zeitlichen Ressourcen, die für die ärztlichen Kernaufgaben zur Verfügung stehen. In Bereichen mit intensiver klinischer Forschung steigen darüberhinaus auch die Anforderungen an die forschungsbegleitende Dokumentation. Eine effiziente Unterstützung bei der Kalkulation, Planung und Durchführung von Therapien durch Informationstechnologische (IT-) Systeme kann eine sinnvolle Entlastung der Ärzte darstellen. Es wurde ein einsatzfähiger Prototyp entwickelt, prgrammiert und implementiert. Anschließend wurde das Ergebnis mit potentiellen Anwendern der Software evaluiert. N2 - With the introduction of diagnoses related groups (DRG) and with other task for quality control, the part of adminitrative task in medical work rises every day. This development has an impact on the timely resources that are available for medical core issues. In departments with intense clinical research, the requirements for research-relatet documentation are rising. An effectiv support in calculation, planing and performing of therapies by modern information technology can bei a vital factor for clincial works. A ready-to-use prototyp of a computer-aided chemotherapy-system has been develepoed, programmed and implemented. Afterwards, the results were evalueted by possible users of this system. KW - Computergestützte Medizin KW - Chemotherapie KW - Onkologie KW - Computer-aided therapy KW - chemotherapy KW - oncology Y1 - 2008 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-37366 ER -